No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
NVCR240816P16000
- 0.60
- +0.15+33.33%
15min DelayClose Jul 19 16:00 ET
0.60High0.60Low
0.60Open0.45Pre Close3 Volume135 Open Interest16.00Strike Price180.00Turnover78.84%IV16.30%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier25DDays to Expiry0.60Extrinsic Value100Contract SizeAmericanOptions Type-0.2152Delta0.0759Gamma35.05Leverage Ratio-0.0214Theta-0.0029Rho-7.54Eff Leverage0.0143Vega
Intraday
- 5D
- Daily
News
CereVasc Announces Appointments of New Directors
CereVasc, Inc., a clinical-stage, medical device company developing novel treatments for neurological diseases, today announced the following...
Breaking Down NovoCure: 4 Analysts Share Their Views
4 analysts have expressed a variety of opinions on NovoCure (NASDAQ:NVCR) over the past quarter, offering a diverse set of opinions from bullish to bearish.The table below provides a concise overview
Novocure Is Maintained at In-Line by Evercore ISI Group
Novocure Is Maintained at In-Line by Evercore ISI Group
Evercore Maintains Novocure(NVCR.US) With Hold Rating, Raises Target Price to $20
Evercore analyst Vijay Kumar maintains $Novocure(NVCR.US)$ with a hold rating, and adjusts the target price from $14.5 to $20.According to TipRanks data, the analyst has a success rate of 47.4% and a
Novocure to Report Second Quarter 2024 Financial Results
ROOT, Switzerland–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2024 on Thursday, July 25, 2024, before the U.S. financial marke
Stocks With the Highest and Lowest Liquidity - Goldman Sachs
Comments
$Novocure(NVCR.US$ pt anyone?
2
$Novocure(NVCR.US$ I placed limit buy @13.1 but got filled at 13.299, I noticed this many times in this app, they are causing slippage, anyone noticed same?
2
$iBio Inc (IBIO.US)$ IBIO: 119% | IBio shares are trading higher after the company collaborated with AstralBio for AI drug-powered antibodies for obesity and cardiometabolic diseases.
DRCT: -49% | Direct Digital Holdings shares are trading lower after the company reported worse-than-expected Q4 financial results.
NVCR: 42% | Novocure shares are trading higher after the company's METIS Phase 3 trial met primary endpoint, demonstrating statistically significant extension in time to intracranial ...
DRCT: -49% | Direct Digital Holdings shares are trading lower after the company reported worse-than-expected Q4 financial results.
NVCR: 42% | Novocure shares are trading higher after the company's METIS Phase 3 trial met primary endpoint, demonstrating statistically significant extension in time to intracranial ...
Morning Movers
Gapping up
$Deutsche Bank(DB.US$ shares rose 3% after Morgan Stanley upgraded the stock to overweight, suggesting further potential growth following a strong performance in 2024.
$Merck & Co(MRK.US$ stock rose 4.8% after its drug for treating a rare lung disease received FDA approval.
$Trump Media & Technology(DJT.US$ stock jumped 14%, following gains after its Nasdaq debut.
$Robinhood(HOOD.US$ stock climbed 6...
Gapping up
$Deutsche Bank(DB.US$ shares rose 3% after Morgan Stanley upgraded the stock to overweight, suggesting further potential growth following a strong performance in 2024.
$Merck & Co(MRK.US$ stock rose 4.8% after its drug for treating a rare lung disease received FDA approval.
$Trump Media & Technology(DJT.US$ stock jumped 14%, following gains after its Nasdaq debut.
$Robinhood(HOOD.US$ stock climbed 6...
34
Key Takeaway
GameStop ( $GameStop(GME.US$ ) and Forge Global ( $Forge Global(FRGE.US$ ) face pre-market declines of 17% and 11% respectively, while Novocure ( $Novocure(NVCR.US$ ) surges 30% on positive trial results.
Merck ( $Merck & Co(MRK.US$ ) gains 4% after FDA approval of its treatment, highlighting a day of significant volatility and strategic moves in the U.S. stock market.
A Glimpse into Quarter-End Moves
As the curtains draw near on...
GameStop ( $GameStop(GME.US$ ) and Forge Global ( $Forge Global(FRGE.US$ ) face pre-market declines of 17% and 11% respectively, while Novocure ( $Novocure(NVCR.US$ ) surges 30% on positive trial results.
Merck ( $Merck & Co(MRK.US$ ) gains 4% after FDA approval of its treatment, highlighting a day of significant volatility and strategic moves in the U.S. stock market.
A Glimpse into Quarter-End Moves
As the curtains draw near on...
1
Read more
灵巧的托拜厄斯 : having
Kenneil NugentOP : lol no help